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Introduction
Familial Mediterranean Fever (FMF) is the most common
hereditary disorder among Armenians. The establish-
ment of clinical and genetic testing of FMF in the Center
of Medical Genetics and Primary Health Care (CMG)
was mostly forced by the high social and public health
problems concerning a huge cohort of patients.
Objectives
Prevalence of FMF is 14-100/per 10000 in different
regions of Armenia. Frequency of carriers of MEFV muta-
tions is 1:3 in Armenians. And, the increase of the inci-
dence of FMF and related disorders is caused by genetic
drift and geographical isolation.
Methods
Molecular genetic detection of 12 MEFV mutations
accounting for 98,71% of patients compared to healthy
individuals revealed the most frequent genotypes and gen-
otype-phenotype correlations.
Results
Heterozygote carriers associated with abortive and mild
FMF features is 18,72%, and 1.29% of patients with clinical
features of FMF are without mutations. In some FMF
patients “mild” MEFV mutations are associated with
inflammatory attacks (P369S: 0.49%; E148Q: 5.09%; A744S:
0.74%). Genotypes E148Q/A744S and E148Q/P369S are
found rarely.
We have revealed the complex FMF cases with follow-
ing concurrent morbidity: epilepsy (M694V/M694V;
V726A/M680I); Sjogren syndrome (M694V/M694V);
bronchial asthma (M694V/V726A, V726A/M680I,
M680I); b-thalassemia (M694V/M694V); hyperthyroidism
(M694V/M680I); Tourette syndrome (M694V/M694V);
Ulcerative colitis (M694V/M694V); renal amyloidosis and
multiple sclerosis (M680I/M680I); ankylosing spondilitis-
like syndrome in about 20% of FMF patients (predomi-
nantly M694V/M694V), etc.
We have shown that particular mutations have signifi-
cant correlation with renal amyloidosis (RA). In frames of
International Meta-FMF project we compared our data
with the FMF morbidity among the other populations. We
confirmed that M694V mutation is a high risk factor of
RA in patients in Armenia, Israel, Lebanon, but not asso-
ciated with RA in Turkey. M694V homozygous genotype
of MEFV in FMF patients with RA is significantly higher
than in patients without RA. The risk of male patients to
develop RA is four times higher than that of female
patients. SAA (Serum Amyloid A) a/a homozygous geno-
type is also associated with a seven-fold increased risk of
developing RA, compared to other SAA1 genotypes. The
presence of only one SAA1 a/a allele does not suggest an
increased susceptibility to RA. In our cohort of FMF
patients the adequate colchicine-therapy may delay RA
progression. In a few cases, the effect of colchicine remains
controversial. M694V homozygotes present a more severe
phenotype and show a limited response to colchicine at
the nephrotic stage of RA. In contrast, FMF patients with
other genotypes still have a good chance to escape the
nephrotic syndrome and to maintain renal function.
Conclusion
As a result of our 16-year experience, the CMG holds the
largest DNA Biobank of FMF (more than 18000 samples).
The number of patients visiting CMG is dramatically
increasing due to complex clinical and genetic examina-
tions, assessment of efficiency of colchicine treatment,
prognosis of development of complications, including
renal amyloidosis, counseling of families, professional and
public awareness. Genetic counseling of FMF patients and
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